Mild cognitive impairment and dementia.
Mild cognitive impairment (MCI) is a clinical syndrome thought to represent the transition between normal function and dementia. This review describes data that support the existence of such a transitional phase, outlines the heterogeneity of MCI and how that has influenced the evolving concept of MCI, and discusses the impact of heterogeneity on recent MCI clinical trials.
Albert
Marilyn S
MS
Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21212, USA. malbert9@jhmi.edu
Blacker
Deborah
D
D000544:Alzheimer Disease / Q000175:diagnosis / Q000523:psychology; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D003072:Cognition Disorders / Q000175:diagnosis* / Q000188:drug therapy / Q000523:psychology; D003704:Dementia / Q000175:diagnosis* / Q000523:psychology; D000077265:Donepezil; D006801:Humans; D007189:Indans / Q000627:therapeutic use; D008960:Models, Psychological; D009483:Neuropsychological Tests / Q000706:statistics & numerical data; D010880:Piperidines / Q000627:therapeutic use; D013577:Syndrome; D009626:Terminology as Topic; D016896:Treatment Outcome
D002800:Cholinesterase Inhibitors; D007189:Indans; D010880:Piperidines; D000077265:Donepezil